SecBot SecBot
PRESS-RELEASE ·Filed May 4, 2026

KRYS

Krystal Biotech, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong revenue growth and pipeline catalysts (KB803, KB801, KB407 data in 2H 2026) support a bullish outlook, but monitor pricing negotiations in Europe and upcoming clinical data readouts.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$286.95
T+0 close · May 4, 2026 · via day close
Latest settled
+26.60%
T+60 · $363.28
Vs SPY
+24.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 4 $286.95entry
  2. T+1 · 7mo ago −0.83%α −1.62% · $284.57
  3. T+5 · 6mo ago +9.04%α +6.10% · $312.88
  4. T+20 · 6mo ago +3.89%α −1.76% · $298.10
  5. T+60 · 4mo ago +26.60%α +24.74% · $363.28
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Krystal Biotech reported strong Q1 2026 results with VYJUVEK revenue up 32% YoY to $116.4M and diluted EPS of $1.83, up 52.5% YoY. Pipeline advancements include complete enrollment for KB803 and on-track readouts for KB801 and KB407 in 2026.

Key Financial Metrics

Gross Margin
95%

Key Facts

  • Q1 2026 VYJUVEK net product revenue of $116.4M, +32% YoY
  • Diluted EPS of $1.83 vs $1.20 in Q1 2025
  • Gross margin of 95% for Q1 2026
  • Registrational studies for KB803 (DEB corneal abrasions) and KB801 (neurotrophic keratitis) on track for data readouts in 2026
  • FDA granted platform technology designation for KB407 (CF) and KB111 (HHD)
  • Cash and investments of $1.0 billion at quarter end
  • FY2026 non-GAAP combined R&D and SG&A expense guidance of $175M-$195M

Financial Impact

Q1 revenue of $116.4M, net income of $55.9M, EPS of $1.83 diluted; significant beat vs prior year

revenueepscash

Risk Factors

  • Pricing and reimbursement negotiations in Germany, France, Italy, and Spain may delay international revenue growth
  • Clinical trial risks for pipeline candidates (KB801, KB407, KB803)
  • Competition from other gene therapies for DEB and other indications

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3286550

Track record

18 reports on KRYS

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.97% at T+20 after the Aug 3, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $295.90 Now $297.90 +0.68% settles Dec 1
  3. Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
  4. Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
  5. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
  6. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
  7. Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
  8. Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
  9. Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
  10. Aug 14, 202613w ago 144 Neutral 2/10 Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (11h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026